Sign inJoin free

Watch / Company News

What's driving Bailador's $22 million H1 net profit

8 Feb 20248:10

What's driving Bailador's $22 million H1 net profit

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Paul Wilson from Bailador Technology Investments talks about how the firm's expansion capital within the venture capital sector, has resulted in the paying out of an interim dividend of three and a half cents, fully franked. The reported a half-year net profit of $22 million, a significant improvement from the previous period's $5 million loss

Wilson explains that the dividend is part of their returns to shareholders strategy, providing investors with access to fast-growing technology companies without sacrificing a dividend. The dividend policy aims to continue indefinitely, supported by franking credits and a strong cash balance.

Site Minder is highlighted as the largest holding in their portfolio, showcasing substantial growth from a $5 million investment to a listed company with a market cap exceeding $1.5 billion. The overall portfolio includes companies in various sectors like travel, health tech, and e-commerce, with a focus on recurring revenue streams and high margins.

Wilson discusses the positive performance of other portfolio companies, including Raised, Instant Scripts, Access Telehealth, Marsh, and Northstowe. The portfolio's growth rate is noted at 41% year on year, with 96% of revenue being recurring in nature and a 66% gross margin. Wilson sees further upside in the portfolio and expresses continued interest in health tech, a large and rapidly growing sector with global market potential.

Find the full unedited transcript of this interview below:

The IT sector focused venture capital firm Bailador Technology, has reported half year net profit of $22 million, compared to a loss of $5 million in the previous period. To get more about these results while it is, co-founder and managing partner Paul Wilson joins me now. Paul, how did you turn things around?

0:21

Oh. Hi, Juliette. Um, we focused heavily on the underlying portfolio. We're very confident that the performance of those companies would continue to be strong. And it was, uh, that was coupled with some improvements in the overall share market and in particular, appetite for technology. So, uh, a blend of those factors produced a very strong result. Net profit, $22 million for the half. And you're also paying out an interim dividend of three and a half cents, fully franked. Um, talk us through the payment to shareholders and how the board came up with this.

0:59

Uh, sure. So, uh, the dividend is an important element of the returns to bilateral shareholders. Of course, as you mentioned, we're a venture capital fund. Or if you want to dig a little deeper, expansion capital within the venture capital sector. And so we have a fast growing portfolio. Uh, we expect to generate most of our returns through capital gains. Uh, but we have significant franking credits. We have a significant cash balance. Uh, we have confidence in the portfolio. So, um, a couple of years ago, we implemented a policy to pay half yearly dividends, fully franked, uh, at 4% of net tangible assets per annum. Uh, given where the share price is at and grossing up for franking credits, that equates to a grossed up yield of 7% at the current share price for BTI investors. Uh, we think it's really, uh, a great step forward for Australian investors to be able to access,

2:00

uh, these very fast growth technology companies at the expansion stage without sacrificing a dividend. Uh, at 7% gross yield, you're building anything. You're going to be getting on cash. Uh, we intend for that policy to continue indefinitely. Uh, we've got Franklin credits sufficient to cover the existing policy. Uh, at this rate, for at least five years, and we anticipate it'll be longer. Uh, so we think it's a really nice balance for investors. You've got, uh, behind you. Some of the companies that you have positions in. I know Site Minder is currently your biggest position. Just talk us through about your overall portfolio and further movement for growth. Sure. Uh, I'll start with Salt Miner. As you mentioned, it is our largest holding. Uh, it's a very good example of what we do at Boulder. We first invested, uh, $5 million in Sidewinder when Sidewinder had revenue of, uh, $5 million. Uh, we have been with it on the journey. Helped them to grow into the global leader that they are

2:59

today in hotel technology. Uh, and a listed company with a market cap in excess of $1.5 billion. Uh, as you can see from that chart that's on screen, site monitor has guided the market for medium term growth of 30%. Uh, moving into underlying EBITDA and cash flow positive this quarter. Uh, this half, I should say, uh, and, uh, and so we expect that journey to continue. I remain on the board of Site Minder, and it's just a wonderful cornerstone in the portfolio. Uh, a number of other companies that are, uh, at various stages of similar journeys, uh, that are in the portfolio, have similar business models to Site Minder, that is, uh, software as a service with a nice recurring revenue stream, high margin, very predictable, lots of measurable unit economics that you can back and, uh, continue to block and tackle whilst achieving strong growth rates. The growth rate across our portfolio is actually even better than sightline. Uh, 41% year on year.

3:59

Uh, for the period just gone, 96% of that revenue is recurring in nature at a 66% gross margin. Uh, so contributors to that include, um, raised, which also operates in the travel sector, but where site monitors, hotels, raised these tours and activities, once again hitting, uh, global markets that are huge addressable market, very strong growth in a terrific product. Uh, we've had some success in the health tech sector. Uh, early in the half, we, uh, sold, uh, together with other shareholders, instant scripts, where we realized $52 million for our position. That was an IRR over 60% per annum. Uh, our other health tech exposures include access telehealth, which lets, uh, consumers, particularly in the regions, uh, and aged care centers, get access to specialists through digital technology. It's making a huge impact on the health outcomes. And the business itself is growing very, very quickly. Uh, Marsh is

4:59

another in the health tech space. It's a platform that is historically focused primarily on men's health, although it does now have a women's offering as well. Uh, rounding out the portfolio, we have, uh, Ross DeFi, which is a market leader in managing, uh, volunteer workforces. Uh, so Red cross and. And others that you can imagine in that space. And then Northstowe takes advantage of e-commerce. It's got a really a very sophisticated offering. Uh, we're investing in Northstowe because a company that we backed early on, Steckler, uh, we sold to Northstowe. We've continued the journey with them and they're headquartered out of the US and Finland. So, um, uh, that's the portfolio company, seven of them. We'd like to have about 8 to 12. So we're definitely in the market looking for new opportunities. We have a number of companies that we're conducting diligence on at the moment. Uh, and uh, we have $94 million in net

5:58

cash. Uh, the other good news is that overall tech prices are low compared to historic levels. Uh, if you use the Bessemer Cloud Index as a, uh, a fairly broad, uh, tech indicator, the, uh, the current multiples are well below, uh, the five year trailing average. That period includes, uh, a pretty sharp rise during Covid. Even if you go back and look at the pre-COVID multiples, uh, they were above where the markets are trading now. So it's a good time to have cash, uh, and a good time to be making investments. Well, an interviewer's dream poll, because I was just going to ask you what else might be on your radar, particularly when, as you say, you sold instant scripts to Wesfarmers for something, I think at a price 25% higher than what had been valued at.

6:47

Yeah. That's right. Look, we pride ourselves on being conservative, on our carrying values. Most of our positions are private companies. And so unlike sightline, where you can just mark market based on the trading, uh, we have to form a view on the value of these private companies. Uh, we very deliberately always try and make sure that we are valuing those positions conservatively and surprise on the upside when we realize cash. Uh, we've had 12 cash realizations. Now, every one of them has been above our carrying value. Uh, at an average of, uh, more than 30% above carrying value. So, um, uh, definitely think this, uh, there's more upside in the portfolio to come continuing that trend. And, uh, just, um, Juliet addressing the other part of your question about what to do next. Uh, we we certainly are still seeing opportunities in health tech. It's a very, uh, large sector, very fast growing sector. And it's one that Australian companies can potentially,

7:47

uh, use to address very large overseas markets as well. Uh, that's something that's been a real theme for bolder is helping Australian tech companies, uh, really succeed in global markets. Uh, I think for our entire existence, more than half the revenue of the portfolio has come from outside of Australia. Uh, that's so that they can become very big very quickly. And that contributes to those value uplifts.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy